Repositorio Dspace

Response to Treatment with Melatonin and Clonazepam versus Placebo in Patients with Burning Mouth Syndrome

Mostrar el registro sencillo del ítem

dc.contributor.author Castillo-Felipe, Candela
dc.contributor.author Tvarijonaviciute, Asta
dc.contributor.author López-Arjona, Marina
dc.contributor.author Pardo-Marín, Luis
dc.contributor.author Pons-Fuster, Eduardo
dc.contributor.author López-Jornet, Pía
dc.date.accessioned 2025-11-18T12:47:44Z
dc.date.available 2025-11-18T12:47:44Z
dc.date.issued 2022-05
dc.identifier.citation Castillo-Felipe C, Tvarijonaviciute A, López-Arjona M, Pardo-Marin L, Pons-Fuster E, López-Jornet P. Response to Treatment with Melatonin and Clonazepam versus Placebo in Patients with Burning Mouth Syndrome. JCM. 29 de abril de 2022;11(9):2516.
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/20933
dc.description.abstract Objective: to evaluate the efficacy of melatonin and clonazepam versus placebo in patients with burning mouth syndrome (BMS). Methods: a prospective double-blind study was carried out in patients with BMS and randomized to three groups: melatonin (1 mg once a day), clonazepam (0.5 mg/twice a day), or a placebo once a day, for 8 weeks. The clinical changes were evaluated, including xerostomia, the Oral Health Impact Profile 14 (OHIP-14) score, Pittsburg Sleep Quality Index, and the Hospital Anxiety and Depression Scale (HADS). Oxygen saturation and heart rate were recorded, with an analysis of salivary biomarkers in the forms of oxytocin, ferritin, adenosine deaminase (ADA), total proteins, and alpha-amylase. Results: a total of 64 patients were analyzed. A significant decrease in burning sensation was recorded with melatonin (7.8 ± 1.54 pre-treatment, 5.78 ± 2.54 post-treatment; p < 0.001) and clonazepam (8.75 ± 1.2 pre-treatment, 5.5 ± 3.6 post-treatment (p < 0.01). With regard to quality of life (OHIP-14), significant improvements were observed before and after the administration of melatonin (p < 0.001) and clonazepam (p = 0.001). On the other hand, with regard to the changes in salivary biomarkers following treatment, negative correlations were found between oxytocin and drainage (r = ?0.410; p = 0.009) and between the HADS-D score and ferritin (r = ?0.312; p = 0.05). While salivary amylase showed positive correlation with heart rate (r = 0.346; p = 0.029) and oxygen saturation (r = 0.419; p = 0.007). Conclusions: melatonin and clonazepam were shown to be effective at reducing the burning sensation and improving quality of life. Both drugs were found to be safe, with no major adverse effects in patients with BMS. Melatonin may be regarded as an alternative treatment for patients with BMS, though further studies are needed to confirm its effectiveness.
dc.language.iso eng
dc.publisher MDPI
dc.rights Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/ *
dc.title Response to Treatment with Melatonin and Clonazepam versus Placebo in Patients with Burning Mouth Syndrome
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 35566642
dc.relation.publisherversion https://www.mdpi.com/2077-0383/11/9/2516
dc.identifier.doi 10.3390/jcm11092516
dc.journal.title Journal of Clinical Medicine
dc.identifier.essn 2077-0383


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta